KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

TAMEing ADPKD with metformin: safe and effective?

Albert C M Ong, Ron T Gansevoort

Kidney Int 100(3) 513-515

PMID34420660
PMCID-
DOI10.1016/j.kint.2021.07.021
发表日期2021-08-23
摘要

摘要

The biguanide metformin has been safely and widely used in the treatment of type 2 diabetes mellitus for decades. Preclinical studies have suggested that it may have a role in slowing disease progression in autosomal dominant polycystic kidney disease. In this issue, Perrone et al. report results from the Trial of Administration of Metformin in PKD (TAME PKD) study, a phase 2 randomized controlled trial investigating the safety and tolerability of metformin in patients in the early stages of autosomal dominant polycystic kidney disease. We discuss the implications of these findings and how they relate to a major phase 3 trial in autosomal dominant polycystic kidney disease that will start later in 2021.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。